Table 1.
Pharmacological agents and concentrations used in the yeast counterparts of human MELAS mutation
| Drug | Concentration | Drug | Concentration | ||
|---|---|---|---|---|---|
| Creatine | 30 µM | 100 µM | Carnitine | 2.5 µM | 10 µM |
| 60 µM | 120 µM | 7.5 µM | 12.5 µM | ||
| Thiamine | 10 µM | 30 µM | Riboflavin | 0.02 µM | 0.06 µM |
| 20 µM | 40 µM | 0.04 µM | 0.08 µM | ||
| Vitamin E | 10 µM | 30 µM | Resveratrol | 10 µM | 30 µM |
| 20 µM | 40 µM | 20 µM | 40 µM | ||
| Vitamin C (ascorbic acid) | 2.5 mM | 10 mM | Lithium | 0.30 mM | 1 mM |
| 7.5 mM | 12.5 mM | 0.60 mM | 1.20 mM | ||
| Menadione | 1 µM | 3 µM | Uridine | 2.5 µM | 10 µM |
| 2 µM | 4 µM | 7.5 µM | 12.5 µM | ||
| Lipoic Acid | 2.5 µM | 10 µM | Coenzyme Q10 (CoQ) | 30 µM | 100 µM |
| 7.5 µM | 12.5 µM | 50 µM | 500 µM | ||
The drugs chosen are pharmacological agents frequently utilized in the treatment of mitochondrial diseases. The drug concentrations were chosen on the basis of their cytotoxic effects. For each drug, the highest concentration shown in the table did not impair the replication capacity of Wt yeast.